在没有匹配的亲缘供者时，家族性单倍型相合的挑战性非亲缘供者异基因造血干细胞移植用于晚期非霍奇金淋巴瘤。 - Suppr

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.

作者信息

Garciaz S, Castagna L, Bouabdallah R, Fürst S, Bramanti S, Coso D, Crocchiolo R, El-Cheikh J, Broussais F, Chabannon C, Santoro A, Blaise D

机构信息

Department of Hematology, Institut Paoli Calmettes, Marseille, France.

Department of Hematology, Humanitas Cancer Center, Rozzano, Italy.

出版信息

Bone Marrow Transplant. 2015 Jun;50(6):865-7. doi: 10.1038/bmt.2015.22. Epub 2015 Mar 2.

DOI:10.1038/bmt.2015.22

PMID:25730187

Abstract

摘要

相似文献

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.在没有匹配的亲缘供者时，家族性单倍型相合的挑战性非亲缘供者异基因造血干细胞移植用于晚期非霍奇金淋巴瘤。

Bone Marrow Transplant. 2015 Jun;50(6):865-7. doi: 10.1038/bmt.2015.22. Epub 2015 Mar 2.

Alternative donor transplant of benign primary hematologic disorders.良性原发性血液系统疾病的替代供体移植

Bone Marrow Transplant. 2015 May;50(5):619-27. doi: 10.1038/bmt.2015.1. Epub 2015 Feb 9.

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.在没有匹配的亲属供者时，家族性单倍体相合挑战性非血缘供者异基因造血干细胞移植用于晚期非霍奇金淋巴瘤。

Bone Marrow Transplant. 2015 Jun;50(6):880. doi: 10.1038/bmt.2015.79.

High frequency of unrecognized indolent hematological disorders among HLA-matched siblings of patients with lymphoproliferative malignancies eligible for allo-SCT.在适合异基因造血干细胞移植的淋巴增殖性恶性肿瘤患者的HLA匹配同胞中，未被识别的惰性血液系统疾病发生率较高。

Bone Marrow Transplant. 2008 Sep;42(6):427-8. doi: 10.1038/bmt.2008.183. Epub 2008 Jun 30.

Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor.干细胞移植供体选择的决策分析——人类白细胞抗原8/8等位基因匹配的无关供体与人类白细胞抗原1抗原错配的相关供体

Blood Cancer J. 2014 Dec 5;4(12):e263. doi: 10.1038/bcj.2014.85.

Who is the best alternative allotransplant donor?谁是最佳的异体移植供体？

Bone Marrow Transplant. 2015 Jun;50 Suppl 2(0 2):S40-2. doi: 10.1038/bmt.2015.94.

Alternative donor transplantation for adults with acute leukemia.成人急性白血病的替代供体移植

Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):272-7. doi: 10.1016/j.beha.2014.10.009. Epub 2014 Oct 15.

J Hematother Stem Cell Res. 2003 Jun;12(3):331-9. doi: 10.1089/152581603322023061.

[Haploidentical hematopoietic stem cell transplantation: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)].[单倍型相合造血干细胞移植：法语国家骨髓移植与细胞治疗协会（SFGM-TC）指南]

Bull Cancer. 2016 Nov;103(11S):S229-S242. doi: 10.1016/j.bulcan.2016.09.007. Epub 2016 Nov 11.

Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.来自 HLA 完全匹配的非同胞亲属的异基因造血干细胞移植的效率：拓展家族搜索的新前景。

Bone Marrow Transplant. 2015 Apr;50(4):545-52. doi: 10.1038/bmt.2014.307. Epub 2015 Jan 26.

引用本文的文献

How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.2025年我们如何采用细胞疗法治疗套细胞淋巴瘤：欧美视角

Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02599-x.

Haploidentical Hematopoietic Stem Cell Transplant Using Post-transplant Cyclophosphamide: A Single-Center Initial Experience in Vietnam.使用移植后环磷酰胺的单倍体相合造血干细胞移植：越南一家单中心的初步经验。

Blood Cell Ther. 2021 Nov 25;4(4):75-83. doi: 10.31547/bct-2021-002.

Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls.淋巴瘤中的单倍体相合干细胞移植：期望与陷阱

J Clin Med. 2020 Nov 7;9(11):3589. doi: 10.3390/jcm9113589.

Blood Adv. 2017 Feb 14;1(6):397-400. doi: 10.1182/bloodadvances.2016002196.

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.在晚期急性髓系白血病和骨髓增生异常综合征中使用移植后环磷酰胺的T细胞充足的单倍体同基因异体移植。

Bone Marrow Transplant. 2016 Feb;51(2):194-8. doi: 10.1038/bmt.2015.270. Epub 2015 Nov 9.

Modern approaches to HLA-haploidentical blood or marrow transplantation.HLA单倍型相合血液或骨髓移植的现代方法。

Nat Rev Clin Oncol. 2016 Jan;13(1):10-24. doi: 10.1038/nrclinonc.2015.128. Epub 2015 Aug 25.

本文引用的文献

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.使用白消安和氟达拉滨进行清髓预处理后，将移植后环磷酰胺作为预防异基因骨髓移植后移植物抗宿主病的单一药物的多机构研究。

J Clin Oncol. 2014 Nov 1;32(31):3497-505. doi: 10.1200/JCO.2013.54.0625. Epub 2014 Sep 29.

Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.与其他替代供体和匹配的同胞移植物相比，未处理的单倍体同基因移植。

Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9. doi: 10.1016/j.bbmt.2014.05.029. Epub 2014 Jun 5.

Experts' considerations on HLA-haploidentical stem cell transplantation.专家对HLA单倍型相合干细胞移植的考量

Eur J Haematol. 2014 Sep;93(3):187-97. doi: 10.1111/ejh.12322. Epub 2014 Apr 26.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.年龄≥40岁的非霍奇金淋巴瘤患者的同种异体移植：无进展生存期令人鼓舞。

Biol Blood Marrow Transplant. 2014 Jul;20(7):960-8. doi: 10.1016/j.bbmt.2014.03.013. Epub 2014 Mar 15.

Biol Blood Marrow Transplant. 2013 Apr;19(4):602-6. doi: 10.1016/j.bbmt.2013.01.006. Epub 2013 Jan 29.

Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.移植后环磷酰胺用于 HLA 单倍体相合骨髓移植中的诱导耐受。

Semin Oncol. 2012 Dec;39(6):683-93. doi: 10.1053/j.seminoncol.2012.09.005.

Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.比较供者移植物 CD34+ 选择与免疫抑制治疗作为完全缓解的急性髓细胞白血病患者 HLA 匹配同胞异基因造血细胞移植后移植物抗宿主病预防的疗效。

J Clin Oncol. 2012 Sep 10;30(26):3194-201. doi: 10.1200/JCO.2012.41.7071. Epub 2012 Aug 6.

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.在接受allo-SCT 的髓系恶性肿瘤患者中，降低强度预处理方案中兔抗胸腺细胞球蛋白剂量从 2.5mg/kg 增加到 5mg/kg，可降低急性和慢性移植物抗宿主病。

Bone Marrow Transplant. 2012 May;47(5):639-45. doi: 10.1038/bmt.2012.3. Epub 2012 Feb 6.

High-dose cyclophosphamide for graft-versus-host disease prevention.大剂量环磷酰胺预防移植物抗宿主病。

Curr Opin Hematol. 2010 Nov;17(6):493-9. doi: 10.1097/MOH.0b013e32833eaf1b.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.非清髓性 HLA 单倍体相合骨髓移植联合大剂量移植后环磷酰胺：HLA 不合对结局的影响。

Biol Blood Marrow Transplant. 2010 Apr;16(4):482-9. doi: 10.1016/j.bbmt.2009.11.011. Epub 2010 Jan 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献